Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study
{{output}}
Background: In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRASG12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorect... ...
